GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Short-Term Debt

ArriVent BioPharma (ArriVent BioPharma) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Short-Term Debt?

ArriVent BioPharma's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.


ArriVent BioPharma Short-Term Debt Historical Data

The historical data trend for ArriVent BioPharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Short-Term Debt Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
- - -

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - -

ArriVent BioPharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


ArriVent BioPharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma (ArriVent BioPharma) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus